S. Awrey

发表

Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy

A. Wyatt, L. Fazli, Tetsutaro Hayashi, 2016, Clinical Cancer Research.

Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer.

L. Fazli, Tetsutaro Hayashi, R. Seiler, 2015, The Journal of urology.

Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa.

Wolfgang Jäger, Yoshiyuki Matsui, Robert H. Bell, 2013, The Journal of urology.

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts

Tetsutaro Hayashi, P. Black, W. Jäger, 2014, Journal of visualized experiments : JoVE.

Construction, expression and characterization of CD45-immunoglobulin fusion proteins

S. Awrey, 1996 .

Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients

C. Collins, S. Volik, M. Gleave, 2016, Genome Biology.

Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer

S. C. Chafe, S. Dedhar, S. Awrey, 2020, Cell reports. Medicine.

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors

P. Rennie, F. Ban, Kriti Singh, 2015, Cells.

Ultrasound-Guided Intramural Inoculation of Orthotopic Bladder Cancer Xenografts: A Novel High-Precision Approach

L. Fazli, Tetsutaro Hayashi, D. Lange, 2013, PloS one.

Harnessing Induced Essentiality: Targeting Carbonic Anhydrase IX and Angiogenesis Reduces Lung Metastasis of Triple Negative Breast Cancer Xenografts

S. Dedhar, S. Awrey, E. Hedlund, 2019, Cancers.

Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors

S. C. Chafe, Frederick S. Vizeacoumar, Franco J. Vizeacoumar, 2021, Science advances.

Hydrogen-deuterium exchange mass spectrometry reveals three unique binding responses of mAbs directed to the catalytic domain of hCAIX

S. C. Chafe, A. Lenferink, S. Dedhar, 2021, mAbs.

Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer

B. Czerniak, C. Dinney, J. Bondaruk, 2013, Molecular Cancer Therapeutics.

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation

R. Young, P. Rennie, Kriti Singh, 2016, Molecular Cancer Therapeutics.

Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies

C. Collins, A. Wyatt, Shawn Anderson, 2015, Oncotarget.

Antineoplastic effects of specific inhibition of Notch-2 in bladder cancer.

L. Fazli, P. Black, K. Gust, 2013 .